ETC-1922159
Cross-source consensus on ETC-1922159 from 1 sources and 4 claims.
1 sources · 4 claims
How it works
Evidence quality
Where it comes from
Highlighted claims
- ETC-1922159 is treated as a PORCN-WNT inhibitor that down-regulates ASCL2 and many other genes in colorectal cancer cells. — Machine learning discoveries of ASCL2-X synergy in ETC-1922159 treated colorectal cancer cells
- The study reanalyzes published colorectal cancer data generated after ETC-1922159 administration. — Machine learning discoveries of ASCL2-X synergy in ETC-1922159 treated colorectal cancer cells
- The extracted text does not provide new dosing schedules or raw expression values for ETC-1922159 treatment. — Machine learning discoveries of ASCL2-X synergy in ETC-1922159 treated colorectal cancer cells
- ETC-1922159 is linked to reduced ASCL2, RNF43, and LGR5 expression through inhibition of PORCN-dependent WNT signaling. — Machine learning discoveries of ASCL2-X synergy in ETC-1922159 treated colorectal cancer cells